Skip to search formSkip to main contentSkip to account menu

Fosamax

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
—Fosamax (Alendronate) is an approved drug widely prescribed for osteoporosis treatment and other bone damaging diseases. Fosamax… 
2009
2009
Objective Studying the treating effect on postmenopausal lower bone mineral density by using traditional Chinese medicine(pigeon… 
2008
2008
Objective:To evaluate the short and long term effects and safety of HRT plus Fosamax or Fosamax on bone mineral density in… 
2007
2007
The 10-year half-life of the bisphosphonate alendronate suggests that its efficacy might persist after discontinuation. To… 
2005
2005
A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both… 
2005
2005
Objective To evaluate the short-and long-term effects of Fosamax on bone mineral density in postmenopausal women with primary… 
1999
1999
Data are submitted on results of investigations designed to study mineral density of the osseous tissue in patients with…